Advances and issues of CAR T cell therapy in B cell lymphoma

doi:10.3969/j.issn.1004-583X.2017.12.002

Clinical Focus

Previous Articles Next Articles

Advances and issues of CAR T cell therapy in B cell lymphoma

Key Laboratory of Pathogenesis and Transformation of Malignant Tumors， Department of Lymphoma，
Ministry of Education， Peking University Cancer Hospital and Beijing Cancer Institute， Beijing 100142， China

Online:2017-12-05 Published:2017-12-14
Contact: Corresponding author: Ying Zhitao， Email: yingzhitao001@163.com

Abstract

Abstract: Chimeric antigen receptor T cell (CAR T) therapy is a novel immunotherapy， which has achieved great success in the past few years. The first product directed against CD19 has been approved by Food and Drug Administration (FDA) for the treatment of relapsed/refractory diffuse large B cell lymphoma in October 2017，which brought the management of lymphoma to a new era. Here， we review the recent advances and unresolved issues in this area. Also， we share the experiences from the CAR T cell trials ongoing at Peking University Cancer Hospital.

Key words: antigens, differentiation, Tlymphocyte;receptors, abtigen, Tcell; , receptor, T cell, lymphoma, , B cell

Ying Zhitao， Zhu Jun. Advances and issues of CAR T cell therapy in B cell lymphoma[J]. Clinical Focus, doi: 10.3969/j.issn.1004-583X.2017.12.002.

Add to citation manager EndNote|Ris|BibTeX

URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2017.12.002

https://huicui.hebmu.edu.cn/EN/Y2017/V32/I12/1017

[1]	Liu Lili, Yuan Yuting, Lai Gengliang, Tian Chuan, Lan Xiang, Ye Zhonglv. The relationship between minimal residual disease on day 15 and prognosis in children with acute lymphoblastic leukemia [J]. Clinical Focus, 2024, 39(1): 47-52.
[2]	Wang Tao, Gao Yuwei, Wang Xinghua, Hu Xiuhong, Cui Hongrui, Xu Baozhen, Yang Hongjuan. Correlation of anti-phospholipase A2 receptor antibody with idiopathic membranous nephropathy [J]. Clinical Focus, 2023, 38(7): 606-612.
[3]	Yang Wei, He Chendong. Primary pulmonary mucosa-associated lymphoid tissue lymphoma with dry cough as the only symptom: A case and literature review [J]. Clinical Focus, 2023, 38(7): 623-627.
[4]	Du Jiayi, Liu Lili, He Yongzhong, Tian Chuan, Lan Xiang, Ye Zhonglyu. Clinical observation of serious adverse events in children with acute lymphoblastic leukemia during chemotherapy [J]. Clinical Focus, 2023, 38(2): 149-154.
[5]	Hu Wencong, Liu Xiuzhen. Two cases of children's anti-MOG antibodies combined with anti-NMDAR antibody double positive autoimmune encephalitis and literature review [J]. Clinical Focus, 2022, 37(8): 733-737.
[6]	Mao Rong, Tao Qianshan, Shen Yuanyuan, Dong Yi. A case with extranodal NK/T cell lymphoma-related hemophagocyte syndrome [J]. Clinical Focus, 2022, 37(7): 635-639.
[7]	Li Shufan, Wang Yuxiu, Jiang Zhenghua. The correlation between the prognosis of lung adenocarcinoma with acquired resistance to the first-generation EGFR TKI and the T790M mutation [J]. Clinical Focus, 2022, 37(11): 985-991.
[8]	Lu Luo, Wang Fei, Gu Weiying. Clinical determination of lymphocyte subsets in peripheral blood of patients with angioimmunoblastic T cell lymphoma [J]. Clinical Focus, 2022, 37(11): 1001-1007.
[9]	Yin Lingling, Wu Wenjian, Zhu Feng. Lineage switch from acute myeloid leukemia to acute lymphoblastic leukemia: A case report and literature review [J]. Clinical Focus, 2022, 37(11): 1025-1030.
[10]	Shen Rui, Lei Yanhua, Jia Haokun. Analysis of the incidence and risk factors for venous thromboembolism in 145 patients with diffuse large B-cell lymphoma [J]. Clinical Focus, 2022, 37(1): 43-45.
[11]	Zhang Xiumin, Zhao Changdong, Li Xue, Lu Xuefeng, Liu Weizhong, Wang Shufang. Relationship between indoleamine 2, 3-dioxygenase and peripheral blood CD4 + in patients with ulcerative colitis [J]. Clinical Focus, 2021, 36(8): 696-698.
[12]	Li Lei, Aaletengqiqige, Zhang Mingchen, Jiang Sheng. Meta-analysis on efficacy and safety of glucagon like peptide-1 receptor agonist on patients with polycystic ovary syndrome [J]. Clinical Focus, 2021, 36(5): 395-401.
[13]	Wang Lingli, Zhao Zhiqiang, Jin Xinrong. Association between rs1799971 polymorphism in mu opioid receptor 1 gene and susceptibility to alcohol dependence: a meta-analysis [J]. Clinical Focus, 2021, 36(4): 303-310.
[14]	He Yiwen, Qiao Tiankui. Clinical value of CEA, CA125, and CYFRA21-1 levels in efficacy evaluation of EGFR-TKIs in the treatment of EGFR mutation-positive non-small cell lung adenocarcinoma [J]. Clinical Focus, 2021, 36(3): 220-224.
[15]	Yang Ke, Chen Jun. Value of serum NSE, CEA and CA125 levels in diagnosis and efficacy evaluation of patients with small cell lung cancer [J]. Clinical Focus, 2021, 36(3): 225-228.

Advances and issues of CAR T cell therapy in B cell lymphoma

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments